[Namespace] Keyword=CONSO NameString=Curation of Neurodegeneration Supporting Ontology DomainString=Other VersionString=20210311 CreatedDateTime=2021-03-11T18:53:54 DescriptionString=The Curation of Neurodegeneration Supporting Ontology (CONSO) contains terms related to neurodegenerative disease and curation of related material. It is not disease-specific, but at least has a focus on Alzheimer's disease. [Author] NameString=Charles Tapley Hoyt CopyrightString=CC0 1.0 Universal [Citation] NameString=CONSO [Processing] CaseSensitiveFlag=yes DelimiterString=| CacheableFlag=yes [Values] 1,3-Thiazole-2,4-diamine|A 2-Bromohexadecanoic acid|A 2-O-sulfated heparin|A 20 S Proteasome|C 3-3 dityrosine cross-linking|A 310-helix|P 3R tau|P 4-OH-GTS-21|A 4R tau|P 4R tauopathy|O 6-O-sulfated heparin|A 8-nitro-cGMP|A A2B5 antigen|P AADvac1|A AAV-FKBP1B|GPR ACY-1215|A AG18051|A AG73|P AICD|P AP-2 complex|C APOE e3|G APOE e4|G APP C-terminally truncated carboxyl-terminal fragments|P APP processing|B APP, ACR|P APP695|PR APP751|PR APP770|PR Abeta*56|A Alpha-synuclein Oligomerization|B Alz50|A Amylin Antagonist AC253|AP Argyrophilic Grain Disease|O Astrogliosis|B Autosomal Dominant Nocturnal Frontal Lobe Epilepsy|O AβOs|A B-973|A BAY61-3606|A Bacterial invasion|B Biphenyl-4-yl-acrylohydroxamoc acids|A Braak_Stage I|A Braak_Stage II|A Braak_Stage III|A Braak_Stage IV|A Braak_Stage V|A Braak_Stage VI|A Brodmann (1909) area 36|A C-30-27|A C31|P C646|A C99|P CA1 field of hippocampus|A CA2 field of hippocampus|A CA3 field of hippocampus|A CA4 field of hippocampus|A CAG repeats|P CDK5R1 p25|GPR CDR - Sum of Boxes|A CGP3466B|A CK1 superfamily|P CLR01|GPR CM-414|A CRL4 complex|C CagA peptide|AP Chemotherapy-induced peripheral neuropathy|O Chronic cerebral hypoperfusion|O Clonal Expansion|O Corticobasal Degeneration|O D6S253|A D6S305|A DAPK, basic loop (BL) motif|P DC11|A DC8E8|A Dopaminergic cell groups|A E1 domain|P E2 domain|P EC102|A EEVD motif|P ER mitochondria interorganellar crosstalk|B Excitotoxicity|O FK1 antibody|A FMR1,(55-200 CGG)|G GA-AGE|A GAL80TS|O GDNF Family|A GLAP|A GPBC, Glycine Receptor 1|P GPBC, alpha-7 nAChR|P GRB10,BPS domain|P GTS-21|A GVD bodies|A Gastrointestinal dysfunctions|O Glutamate excitotoxicity|B HDAC3 inhibitor|A Histone H3|GPR Hsp27 oligomers|A Hyperamylinemia|O ID-8|A IκB kinase|C Jcasp|P KU-177|A KXGS motif|P Kalirin 7|PR LDN-193594|A LDN-193665|A LDN-213843|A LMW amyloid oligomers|A LPLI|O LY293002|A Long-Term Depression|O MARK4 isoform 2 (688 aa)|PR MLS000034832|A MN423|A MPT0G211|A MTHFR,TT+AA|A Microgliosis|B Mini-Mental Status Exam|A Mitochondrial pathway|B Mori Fructus ethanol extract|A Motor Neurons|A Muscles|A N-AcGIP|A N-terminal fragment of APP|P N-terminal fragment of ATF6|P NP_001387.2:p.Arg205del|P NP_001387.2:p.Glu239del|P Neural Stem Cell|A Neurites|A Neurodegeneration|O Neuroglia|A Notch intracellular domain|P O-GlcNAcylation|T OSW-1|A P3 peptide|P PARK7-alpha helices|P PDR-1|GPR PI3K-Akt signaling pathway|B PINK-1|GPR PINK1-Park pathway|B PTI-125|A Pars Compacta|A Pathological Tau Spreading|O Peripheral Tissue|A Phenylthiazolyl-hydrazide|A PrP106-126|P PrPSc|PR Pro3-GIP|A Proteostasis|B Purkinje cell layer of cerebellar cortex|A Q82 aggregates|A RAC1b|PR RGFP136|A RGFP966|A RM-532-46|A S 24795|A SEN-1269|A SK and F 77434|A SL-327|A ST7612AA1|A Serpin-enzyme complex receptor|GPR Spinocerebellar Ataxia 11|O Syndecan Family|P TDP-43 aggregates|A TDP-43 oligomers|A TGM2 Isoform 3 (349 aa)|PR TIM/TOM complex|C TOC1|A Tau 6D|PR Tau 6P|PR Tau C3|P Tau MN423|P Tau Protein Secondary Structure, Turn|A Tau aggregates|A Tau aggregation inhibitor|A Tau annular protofibrils|A Tau antibody|A Tau antibody, 40E8|A Tau antibody, 4E4|A Tau antibody, 6C5|A Tau antibody, AGG5759|A Tau antibody, HT7|A Tau antibody, MC1|A Tau antibody, RG7345|A Tau antibody, TNT1|A Tau antibody, TNT2|A Tau antibody, Tau-13|A Tau antibody, Tau46|A Tau antibody, pS396|A Tau dimers|A Tau epitope|P Tau epitope, 12E8|P Tau epitope, AD2|P Tau epitope, AP422|P Tau epitope, AT100|P Tau epitope, AT180|P Tau epitope, AT270|P Tau epitope, AT8|P Tau epitope, CP13|P Tau epitope, PHF1|P Tau fibrils|A Tau isoform A (316 aa)|PR Tau isoform B (381 aa)|PR Tau isoform C (410 aa)|PR Tau isoform D (383 aa)|PR Tau isoform E (412 aa)|PR Tau isoform F (441 aa)|PR Tau isoform Fetal-tau (352 aa)|PR Tau oligomers|A Thiamet G|A Thioflavin S|A Trithiocarbonates|A Tubacin|A Tubastatin A|A UBB+1|P USP14 Aptamer|A VQIINK motif|P VQIVYK motif|P VU0029767|A VU0090157|A VU0152099|A VU0184670|A VU0456940|A VU10010|A Ventral Tegmental Area|A YENPTY endocytosis motif (APP)|P [125I]-NCQ 298|A aMCI|O abf-2|GPR advanced glycation end product|A alpha-2 beta-2 nAChR|C alpha-3 beta-2 nAChR|C alpha-3 beta-3 beta-4 nAChR|C alpha-3 beta-4 nAChR|C alpha-4 alpha-5 beta-2 nAChR|C alpha-4 beta-2 nAChR|C alpha-4 beta-4 nAChR|C alpha-4-containing nAChR|C alpha-6 alpha-4 beta-2 beta-3 nAChR|C alpha-6 beta-2 beta-3 nAChR|C alpha-6-containing nAChR|C alpha-7 beta-2 nAChR|C alpha-7-containing nAChR|C alpha-Bungarotoxin|GPR alpha-synuclein aggregates|A alpha-synuclein fibrils|A alpha-synuclein oligomers|A alternative splicing of APP gene|B amyloid-beta 40 oligomers|A amyloid-beta 42 oligomers|A amyloid-beta aggregates|A amyloid-beta antibody, NU1|A amyloid-beta derived diffusible ligands|A amyloid-beta fibrils|A amyloid-beta oligomers|A amyloidogenesis|B assembly domain|P bb14|A beta-2-containing nAChR|C caprospinol|A ced-9|GPR cerebral cortex|A chemofog|O cholinergic neuron|A cis p-tau|GPR cleaved PINK1|P clec-4|GPR clec-65|GPR cmp16|A common fragile site|A crebinostat|A cystein-dependent auto-acetylation|B deamidation|T dense core plaques|A detyrosination|T diaminothiazole|A dopamine homeostasis|B dystrophic neurite|A entorhinal cortex layer 2|A exotoxin A|GPR formylation|T gamma-secretase|C ghost tangles|A glycation|T granular layer of cerebellar cortex|A granular tau oligomers|A granulovacuolar degeneration|O growth factor|A heat shock proteins|P high-calorie diets|O hsp-16|GPR huntingtin aggregates|A hydrophobic pocket of actin|P hyperphosphorylation|T hyposmia|O indirubin|A isocarboxazide|A isolation rearing|O isopentanyladenine|A kappa-Bungarotoxin|GPR lgg-1|GPR long-term potentiation|A lys-2|GPR maitotoxin|A mdMCI|O mevalonate pathway|B microtubule-binding region|P midbrain dopaminergic neuron|A misfolded|T misfolding|B mitochondrial DAMPs|A mitochondrial aggregation|B mitochondrial dysfunction|O mitochondrial homeostasis|B mitochondrial motility|B mitochondrial precursor protein|GPR molecular layer of cerebellar cortex|A nAChR assembly|B nasal cycle|A neurite retraction|O neuroinflammation|O neurotoxicity|O neurovascular unit|A neutral sphingomyelinase|P nitration|T non-enzymatic protein modification|B non-shivering thermogenesis|B noradrenergic neuron|A olfactory epithelium|A olomoucine|A oxazolidinedione|A oxidative protein folding|B p83|P paired helical filaments|A peripheral nervous system injury|O phosphatase-activating domain|P pof14|A polyQ aggregates|A polyamination|T polysumoylation|T prefibrillar α-synuclein oligomers|A pretangles|A projection domain|P proline-rich domain|P proline-rich region 1|P proline-rich region 2|P protein aggregates|A protein aggregation|B proteotoxicity|O sAPP-alpha|GPR sAPP-beta|GPR sAPP-gamma|P skn-1|GPR sonicated tau fibrils|A ss20399075|G straight filaments|A sudoxicam|A tau polyclonal antibody|A thiohydantoin|A thioxooxazolidine|A tideglusib|A tubulin detyrosination|T tubulin-binding repeat 1|P tubulin-binding repeat 2|P tubulin-binding repeat 3|P tubulin-binding repeat 4|P tunneling nanotubes|A